logo-loader
viewAchieve Life Sciences Inc

Achieve Life Sciences shares continue to soar on the back of 4Q earnings results

The company reported 4Q earnings per share of US$0.55, $0.09 better than analyst estimates of $0.64

smoking
The pharmaceutical group specializes in smoking-cessation techniques

Achieve Life Sciences Inc (NASDAQ:ACHV) shares soared on Friday on the back of year-end and fourth-quarter earnings results that beat analyst estimates.  

Shares of the Washington State-based biotech moved significantly throughout the day on Friday, up 31% at US$3.21 by mid-day. The pharmaceutical group specializes in smoking-cessation techniques. 

The company reported 4Q earnings per share of US$0.55, $0.09 better than analyst estimates of $0.64. 

READ: Achieve Life Sciences shares rocket after promising smoking-cessation drug trial

The company's net loss for the fourth quarter was US$3.6 million. For the year ended December 31, 2018, it was US$12.7 million. 

As of December 31, 2018, the company's cash, cash equivalents, short-term investments and restricted cash were US$14.7 million. Total operating expenses for the fourth quarter and year ended December 31, 2018 were $3.7 million and $12.8 million, respectively. 

The company recently released news that it had completed the enrollment in a Phase 2b trial of its smoking-cessation drug, cytisinicline.  The plant-based compound, also known as cytisine, interacts with the brain’s nicotine receptors to reduce nicotine withdrawal symptoms.

It also recently presented final data from its cytisinicline phase 1/2 multi-dose, pharmacokinetic and pharmacodynamics study at the Society for Research on Nicotine & Tobacco Annual Meeting. 

Contact Katie Lewis at [email protected]

-- story updated to reflect share price movement on Friday -- 

Quick facts: Achieve Life Sciences Inc

Price: 0.3186 USD

NASDAQ:ACHV
Market: NASDAQ
Market Cap: $9.99 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

OptiBiotix Health secures significant exclusive licence agreement for OptiBiome

OptiBiotix Health PLC's (LON:OPTI) Stephen O'Hara chats to Proactive's Andrew Scott after signing an exclusive licence agreement for its OptiBiome weight loss ingredient with Australian firm OptiPharm Pty Ltd. OptiPharm owns Optislim, the number one weight management brand in Australia, which...

10 hours, 1 minute ago

2 min read